Chronic Myelomonocytic Leukemia clinical trials at UCSF

1 research study open to eligible people

Chronic myelomonocytic leukemia causes harmful changes in blood cells. UCSF is conducting trials with stem cell transplants from donors who are not fully matched. Researchers focus on using reduced doses of drugs to explore better treatment options.

Showing trials for

  • HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: - Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? - Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?

    San Francisco, California and other locations

Our lead scientists for Chronic Myelomonocytic Leukemia research studies include .

Last updated: